| Value | ₹285.0 Cr |
|---|
BSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹731.70
- Market cap
- ₹11,517 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.5×Sector 45.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Other credit rating announcements
All →Supra Pacific Financial Services Credit Rating
Acuité assigned ACUITE BBB-/Stable to Supra Pacific Financial's bank loan facilities. The rating letter is dated 30 October 2026.
Apollo Pipes Credit Rating
Apollo Pipes Limited's bank facilities worth Rs. 150 Crore were upgraded by ICRA to [ICRA]AA-(Stable)/[ICRA]A1+ from A+. The rationale cites deeper integration with the APL Apollo Group.
Ashoka Buildcon Credit Rating
ICRA reaffirmed and then withdrew Ashoka Buildcon's short-term debt rating of [ICRA] A1+ at the company's request. Other debt instruments remain rated by other agencies.
Rolex Rings Credit Rating
Rolex Rings' credit rating was upgraded by CARE Ratings: long-term bank facilities moved from CARE A- to CARE A, and short-term from CARE A2+ to CARE A1. The upgrade reflects a stronger credit profile.
Mangalam Global Enterprise Credit Rating
Infomerics reaffirmed Mangalam Global's IVR BBB rating, revised outlook to Negative and moved it to Issuer Not Cooperating. Rating action dated 29 October 2026.
DCM Shriram Credit Rating
DCM Shriram reaffirmed ICRA ratings on its long-term and short-term bank facilities and fixed deposit programme. Commercial paper rating was reaffirmed and withdrawn, with no change in rating levels.